Rockefeller Capital Management L.P. Has $26.14 Million Stake in Cencora, Inc. (NYSE:COR)

Rockefeller Capital Management L.P. increased its position in Cencora, Inc. (NYSE:COR) by 5.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 116,120 shares of the company’s stock after acquiring an additional 5,840 shares during the period. Rockefeller Capital Management L.P.’s holdings in Cencora were worth $26,137,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in COR. B. Riley Wealth Advisors Inc. bought a new position in shares of Cencora during the 1st quarter valued at $411,000. LRI Investments LLC acquired a new position in Cencora during the first quarter worth $31,000. Cetera Investment Advisers bought a new position in Cencora during the first quarter valued at about $16,625,000. Cetera Advisors LLC acquired a new stake in shares of Cencora in the first quarter worth about $2,091,000. Finally, EverSource Wealth Advisors LLC bought a new stake in shares of Cencora during the 1st quarter worth about $325,000. Institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the transaction, the chairman now directly owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 93,018 shares of company stock valued at $22,478,942. 15.80% of the stock is owned by corporate insiders.

Cencora Stock Up 0.7 %

NYSE COR opened at $251.55 on Friday. Cencora, Inc. has a twelve month low of $195.83 and a twelve month high of $253.27. The stock has a market cap of $49.57 billion, a PE ratio of 33.50, a PEG ratio of 1.66 and a beta of 0.44. The firm has a 50-day simple moving average of $234.91 and a 200 day simple moving average of $232.53. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.87%. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio (DPR) is currently 29.29%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Bank of America reaffirmed a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Evercore ISI lifted their target price on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, Barclays upped their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $271.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.